Trends in medicines procurement by the Brazilian federal government from 2006 to 2013

Abstract

The costs of medicines pose a growing burden on healthcare systems worldwide. A comprehensive understanding of current procurement processes provides strong support for the development of effective policies. This study examined Brazilian Federal Government pharmaceutical procurement data provided by the Integrated System for the Administration of General Services (SIASG) database, from 2006 to 2013. Medicine purchases were aggregated by volume and expenditure for each year. Data on expenditure were adjusted for inflation using the Extended National Consumer Price Index (IPCA) for December 31, 2013. Lorenz distribution curves were used to study the cumulative proportion of purchased therapeutic classes. Expenditure variance analysis was performed to determine the impact of each factor, price and/or volume, on total expenditure variation. Annual expenditure on medicines increased 2.72 times, while the purchased volume of drugs increased 1.99 times. A limited number of therapeutic classes dominated expenditure each year. Drugs for infectious diseases drove the increase in expenditures from 2006 to 2009 but were replaced by antineoplastic and immunomodulating agents beginning in 2010. Immunosuppressants (L04), accounted for one third of purchases since 2010, showing the most substantial growth in expenditures during the period (250-fold increase). The overwhelming price-related increase in expenditures caused by these medicines is bound to have a relevant impact on the sustainability of the pharmaceutical supply system. We observed increasing trends in expenditures, especially in specific therapeutic classes. We propose the development and implementation of better medicine procurement systems, and strategies to allow for monitoring of product price, effectiveness, and safety. This must be done with ongoing assessment of pharmaceutical innovations, therapeutic value and budget impact.

Sharp rise in the expenditures of targeted drugs in Ecuador: five-year (2010-2014) consumption of oncologic drugs in public and private hospitals

“…The rising pattern is totally driven by the expenditures on targeted drugs. Similar results have been described in other Latin American countries; for instance, the Brazilian public expending on cancer drugs increased by 20 between 2006 and 2013, [25] and the Colombian expending on high cost drugs increased by six from 2005 to 2010. [23] The mean expenditure per patient on targeted drugs presented a similar trend, meaning either new even more expensive targeted drugs continued reaching the market, [26] the shift from classic chemotherapy to new targeted drugs kept fast, or prices of drugs readily available kept raising.…”

Policies influencing access to new targeted oncologic drugs in Ecuadorian hospitals: an interrupted time series analysis

“…The study showed an increasing utilization of new oncologic targeted drugs during the last years, leading to an important impact over the total national expenditure on cancer drugs. Similar figures have been described for Colombia and Brazil . Therefore, it becomes crucial to manage the inclusion of new health technologies under an evidence‐based perspective, whilst keeping in mind the permanent constraints on the availability of financial resources .…”

The High “Cost” of Experimental Drugs Obtained Through Health Litigation in Brazil

“…The medicines in classes L01 (antineoplastic agents), L02 (hormones), and L04 (immunosuppressants) are among the most expensive and most often incorporated since 2012. An analysis of expenses with medicines incorporation showed that class L corresponded to a greater variation in expenses between 2006 and 2013, with a 20-fold increase, while class L04 increased 250 times in the Brazilian federal government expenses (Luz et al, 2017). This medicine class was also responsible for high expenses in the United States, United Kingdom, Australia and Canada (Alves et al, 2018).…”